A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...

The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took another zig on Thursday with a federal appellate court blocking the ...

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto. Novartis on Thursday secured a last-minute win against MSN ...

No­var­tis is the lat­est drug­mak­er to sue the gov­ern­ment for al­leged­ly re­ject­ing its pro­posed mod­el to dis­trib­ute fed­er­al drug dis­counts.

Novartis AG is challenging a federal health agency’s decision to rejects its proposal to discount drugs as a rebate rather than up-front to health providers that treat lower-income and uninsured ...

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

WASHINGTON, Jan 16 - Novartis (NOVN.S), opens new tab won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic ...

Basel: Novartis has announced that the Company is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the ...

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday.

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ® (sacubitril/valsartan ...